Amyloid-lowering monoclonal antibody (mAb) therapies for early symptomatic Alzheimer’s disease, including mild cognitive impairment and mild dementia, have generated new excitement about the future of treatment for this progressive condition. These treatments aim to slow or halt the progression of Alzheimer's disease by tackling an underlying cause of the disease – not just managing its symptoms. The evidence shows that individuals receiving these therapies can experience slower disease progression and the potential to extend their independence in everyday life.  This GSA Momentum Discussion webinar, recorded at the GSA 2025 Annual Scientific Meeting, highlights the clinical outcomes associated with mAb therapies through the reflections of patients receiving the treatments and those who support them. 

Support provided by Eisai. 

Transcript

Speakers

• Tracy Collins, Person living with early-onset Alzheimer’s disease
• Scott Hardy, Care partner to Tracy

Host

Jennifer Pettis, MS, RN, CNE, Director, Strategic Alliances, Gerontological Society of America